1. School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, China; 2. Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China
Abstract：Inoculation of COVID-19 vaccines is an important approach to preventing SARS-CoV-2 infections and reducing the severe disease and mortality of COVID-19. The elderly, children and adolescents, pregnant women, lactating women, patients with chronic diseases and immunocompromised individuals are considered to be susceptible to and at a high risk of COVID-19. Early, safe and effective inoculation of COVID-19 vaccines is critical for the successful building of the population immune barrier against COVID-19. This review, based on data from clinical trials, summarizes the safety and efficacy and safety of COVID-19 vaccines among special populations, so as to provide insights into COVID-19 vaccination among special populations.
[1] 陈恩富. 疫苗时代新型冠状病毒肺炎疫情防控策略[J]. 预防医学,2021,33(3):221-225. CHEN E F.Prevention and control strategy of COVID-19 in the vaccine era[J]. Prev Med, 2021,33(3):221-225. [2] 中华人民共和国国家卫生健康委员会.新冠病毒疫苗接种技术指南(第一版)[J]. 传染病信息,2021,34(2):97-98. National Health Commission of the People's Republic of China.Technological guideline for COVID-19 vaccination[J].Infect Dis Inf,2021,34(2):97-98. [3] COVID19 Vaccine Tracker Team.Approved vaccines[EB/OL](2021-12-29)[2022-03-08].https://covid19.trackvaccines.org/vaccines/approved/#vaccine-list. [4] POLACK F P,THOMAS S J,KITCHIN N,et al.Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine[J].N Engl J Med,2020,383(27):2603-2615. [5] BADEN L R,EL SAHLY H M,ESSINK B,et al.Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine[J].N Engl J Med,2021,384(5):403-416. [6] ZHANG J,HU Z,HE J,et al.Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine(V-01)for COVID-19 in healthy adults:a randomized,double-blind,placebo-controlled,phase Ⅰ trial[J].Emerg Microbes Infect,2021,10(1):1589-1597. [7] WU Z,HU Y,XU M,et al.Safety,tolerability,and immunogenicity of an inactivated SARS-CoV-2 vaccine(CoronaVac)in healthy adults aged 60 years and older:a randomised,double-blind,placebo-controlled,phase 1/2 clinical trial[J].Lancet Infect Dis,2021,21(6):803-812. [8] XIA S L,ZHANG Y T,WANG Y X,et al.Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,BBIBP-CorV:a randomised,double-blind,placebo-controlled,phase 1/2 trial[J].Lancet Infect Dis,2021,21(1):39-51. [9] ZAKARYA K,KUTUMBETOV L,ORYNBAYEV M,et al.Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults:a single-centre,randomised,single-blind,placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan[J/OL].EClinicalMedicine,2021,39(2021-08-13)[2022-03-08].https://doi.org/10.1016/j.eclinm.2021.101078. [10] RAMASAMY M N,MINASSIAN A M,EWER K J,et al.Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002):a single-blind,randomised,controlled,phase 2/3 trial[J].Lancet,2021,396(10267):1979-1993. [11] ZHU F C,GUAN X H,LI Y H,et al.Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older:a randomised,double-blind,placebo-controlled,phase 2 trial[J].Lancet,2020,396(10249):479-488. [12] SADOFF J,GRAY G,VANDEBOSCH A,et al.Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19[J].N Engl J Med,2021,384(23):2187-2201. [13] LOGUNOV D Y,DOLZHIKOVA I V,SHCHEBLYAKOV D V,et al.Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine:an interim analysis of a randomised controlled phase 3 trial in Russia[J].Lancet,2021,397(10275):671-681. [14] QIU H Y,WU J H,HONG L,et al.Clinical and epidemiological features of 36 children with coronavirus disease 2019(COVID-19)in Zhejiang,China:an observational cohort study[J].Lancet Infect Dis,2020,20(6):689-696. [15] ALI K,BERMAN G,ZHOU H,et al.Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents[J/OL].N Engl J Med(2021-12-09)[2022-03-08].https://doi.org/10.1056/NEJMoa2109522. [16] FRENCK R W,JR.,KLEIN N P,KITCHIN N,et al.Safety,immunogenicity,and efficacy of the BNT162b2 Covid-19 vaccine in adolescents[J].N Engl J Med,2021,385(3):239-250. [17] HAN B H,SONG Y F,LI C G,et al.Safety,tolerability,and immunogenicity of an inactivated SARS-CoV-2 vaccine(CoronaVac)in healthy children and adolescents:a double-blind,randomised,controlled,phase 1/2 clinical trial[J].Lancet Infect Dis,2021,21(12):1645-1653. [18] XIA S L,ZHANG Y T,WANG Y X,et al.Safety and immunogenicity of an inactivated COVID-19 vaccine,BBIBP-CorV,in people younger than 18 years:a randomised,double-blind,controlled,phase 1/2 trial[J].Lancet Infect Dis,2022,22(2):196-208. [19] PRINCIPI N,ESPOSITO S.Is the immunization of pregnant women against COVID-19 justified?[J/OL].Vaccines,2021,9(9)[2022-03-08]. https://doi.org/10.3390/vaccines9090970. [20] DAGAN N,BARDA N,BIRON-SHENTAL T,et al.Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy[J].Nat Med,2021,27(10):1693-1695. [21] KHARBANDA E O,HAAPALA J,DE SILVA M,et al.Spontaneous abortion following COVID-19 vaccination during pregnancy[J].JAMA,326(16):1629-1631. [22] CHAREPE N,GONÇALVES J,JULIANO A M,et al. COVID-19 mRNA vaccine and antibody response in lactating women:a prospective cohort study[J/OL]. BMC Pregnancy Childbirth,2021,21[2022-03-08]. https://doi.org/10.1186/s12884-021-04051-6. [23] ALI H,ALTERKI A,SINDHU S,et al.Robust antibody levels in both diabetic and non-diabetic individuals after BNT162b2 mRNA COVID-19 vaccination[J/OL].Front Immunol(2021-11-24)[2022-03-08].https://doi.org/10.3389/fimmu.2021.752233. [24] CHOWDHURY O,BRUGUIER H,MALLETT G,et al.Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms[J].Br J Haematol,2021,194(6):1010-1015. [25] PIMPINELLI F,MARCHESI F,PIAGGIO G,et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment:preliminary data from a single institution [J/OL]. J Hematol Oncol,2021,14[2022-03-08].https://doi.org/10.1186/s13045-021-01090-6. [26] MAZZOLA A,TODESCO E,DROUIN S,et al.Poor antibody response after two doses of SARS-CoV-2 vaccine in transplant recipients[J/OL].Clin Infect Dis(2021-06-24)[2022-03-08].https://doi.org/10.1093/cid/ciab580. [27] RABINOWICH L,GRUPPER A,BARUCH R,et al.Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients[J].J Hepatol,2021,75(2):435-438. [28] CORNBERG M,BUTI M,EBERHARDT C S,et al.EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases,hepatobiliary cancer and liver transplant recipients[J].J Hepatol,2021,74(4):944-951. [29] FIX O K,BLUMBERG E A,CHANG K M,et al.American Association for the Study of Liver Diseases expert panel consensus statement:vaccines to prevent coronavirus disease 2019 infection in patients with liver disease[J].Hepatology,2021,74(2):1049-1064. [30] FENG Y M,ZHANG Y F,HE Z Y F,et al.Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1:a non-randomized cohort study[J/OL].EClinicalMedicine(2021-12-04)[2022-03-08].https://doi.org/10.1016/j.eclinm.2021.101226. [31] MADHI S A,KOEN A L,IZU A,et al.Safety and immunogenicity of the ChAdOx1 nCoV-19(AZD1222)vaccine against SARS-CoV-2 in people living with and without HIV in South Africa:an interim analysis of a randomised,double-blind,placebo-controlled,phase 1B/2A trial[J].Lancet HIV,2021,8(9):568-580. [32] FRATER J,EWER K J,OGBE A,et al.Safety and immunogenicity of the ChAdOx1 nCoV-19(AZD1222)vaccine against SARS-CoV-2 in HIV infection:a single-arm substudy of a phase 2/3 clinical trial[J]. Lancet HIV,2021,8(8):474-485.
